Article Details

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design ...

Retrieved on: 2022-02-25 11:09:36

Tags for this article:

Click the tags to see associated articles and topics

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design .... View article details on hiswai:

Excerpt

... fully-human polyclonal antibodies without the need for human donors, ... comparator—a monoclonal antibody cocktail (casirivimab and imdevimab) ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up